Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Dario Neri
Cancer Immunology Research (2019) Vol. 7, Iss. 3, pp. 348-354
Open Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

Development of therapeutic antibodies for the treatment of diseases
Ruei‐Min Lu, Yu‐Chyi Hwang, I-Ju Liu, et al.
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 1732
Enhancing cancer immunotherapy with nanomedicine
Darrell J. Irvine, Eric L. Dane
Nature reviews. Immunology (2020) Vol. 20, Iss. 5, pp. 321-334
Open Access | Times Cited: 670
Emerging new therapeutic antibody derivatives for cancer treatment
Shijie Jin, Yanping Sun, Liang Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 319
Multispecific drugs herald a new era of biopharmaceutical innovation
Raymond J. Deshaies
Nature (2020) Vol. 580, Iss. 7803, pp. 329-338
Closed Access | Times Cited: 224
Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours
Aslan Mansurov, Jun Ishihara, Peyman Hosseinchi, et al.
Nature Biomedical Engineering (2020) Vol. 4, Iss. 5, pp. 531-543
Open Access | Times Cited: 192
Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation
Heng Zhang, Yu Han, Yuanfan Yang, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 40, pp. 16377-16382
Closed Access | Times Cited: 154
Designing antibodies as therapeutics
Paul J. Carter, Arvind Rajpal
Cell (2022) Vol. 185, Iss. 15, pp. 2789-2805
Open Access | Times Cited: 137
Advances in antibody-based therapy in oncology
Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nature Cancer (2023) Vol. 4, Iss. 2, pp. 165-180
Closed Access | Times Cited: 119
Engineering interferons and interleukins for cancer immunotherapy
Patrick G. Holder, Shion A. Lim, Christine Huang, et al.
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114112-114112
Open Access | Times Cited: 95
Targeted modulation of immune cells and tissues using engineered biomaterials
Parisa Yousefpour, Kaiyuan Ni, Darrell J. Irvine
Nature Reviews Bioengineering (2023) Vol. 1, Iss. 2, pp. 107-124
Open Access | Times Cited: 83
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 65
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 34
Targets and Antibody Formats for Immunotherapy of Neuroblastoma
Jeong A Park, Nai‐Kong V. Cheung
Journal of Clinical Oncology (2020) Vol. 38, Iss. 16, pp. 1836-1848
Open Access | Times Cited: 106
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Tobias Weiß, Emanuele Puca, Manuela Silginer, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 564
Closed Access | Times Cited: 99
Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy
Jenniffer Linares, Juan A. Marín‐Jiménez, Jordi Badia-Ramentol, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 8
Open Access | Times Cited: 77
Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Ivan S. Pires, Paula T. Hammond, Darrell J. Irvine
Advanced Therapeutics (2021) Vol. 4, Iss. 8
Open Access | Times Cited: 73
ADCdb: the database of antibody–drug conjugates
Liteng Shen, Xiuna Sun, Zhen Chen, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1097-D1109
Open Access | Times Cited: 31
Scan and Unlock: A Programmable DNA Molecular Automaton for Cell‐Selective Activation of Ligand‐Based Signaling
Jinghui Zhang, Zongyang Qiu, Jiahui Fan, et al.
Angewandte Chemie International Edition (2020) Vol. 60, Iss. 12, pp. 6733-6743
Closed Access | Times Cited: 58
Cytokine engineering for targeted cancer immunotherapy
Lucia Bonati, Li Tang
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 43-52
Open Access | Times Cited: 55
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
Yuanming Xu, Lucia Campos Carrascosa, Yik A. Yeung, et al.
Cancer Immunology Research (2021) Vol. 9, Iss. 10, pp. 1141-1157
Open Access | Times Cited: 54
Improved GPCR ligands from nanobody tethering
Ross W. Cheloha, Fabian A. Fischer, Andrew W. Woodham, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 51
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy
Emily De Lombaerde, Olivier De Wever, Bruno G. De Geest
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1875, Iss. 2, pp. 188526-188526
Closed Access | Times Cited: 47
Cell-specific aptamers as potential drugs in therapeutic applications: A review of current progress
Jieyu Yuhan, Liye Zhu, Longjiao Zhu, et al.
Journal of Controlled Release (2022) Vol. 346, pp. 405-420
Closed Access | Times Cited: 28
Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
Péter A. Szijj, Melissa A. Gray, Mikaela K. Ribi, et al.
Nature Chemistry (2023) Vol. 15, Iss. 11, pp. 1636-1647
Open Access | Times Cited: 20
Active Ingredients from Chinese Medicine for Combination Cancer Therapy
Xuan Wang, Jing Li, Ruie Chen, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 11, pp. 3499-3525
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top